Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
MK-1084
i
Other names:
MK-1084, MK 1084, MK1084
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(2)
News
Trials
Company:
Merck (MSD), Otsuka
Drug class:
KRAS G12C inhibitor
Related drugs:
‹
sotorasib (76)
adagrasib (35)
RG6330 (6)
D-1553 (6)
fulzerasib (4)
ZG19018 (4)
JAB-21822 (4)
APG-1842 (3)
ARS-1620 (2)
BI 1823911 (2)
JDQ443 (2)
ABSK071 (1)
AZ’8037 (1)
GEC-255 (1)
RM-029 (1)
YL-17231 (1)
D3S-001 (0)
FWD-K01 (0)
GH35 (0)
HBI-2438 (0)
HS-10370 (0)
RMC-6291 (0)
UCT-001024 (0)
VRTX126 (0)
YL-15293 (0)
LY3537982 (0)
sotorasib (76)
adagrasib (35)
RG6330 (6)
D-1553 (6)
fulzerasib (4)
ZG19018 (4)
JAB-21822 (4)
APG-1842 (3)
ARS-1620 (2)
BI 1823911 (2)
JDQ443 (2)
ABSK071 (1)
AZ’8037 (1)
GEC-255 (1)
RM-029 (1)
YL-17231 (1)
D3S-001 (0)
FWD-K01 (0)
GH35 (0)
HBI-2438 (0)
HS-10370 (0)
RMC-6291 (0)
UCT-001024 (0)
VRTX126 (0)
YL-15293 (0)
LY3537982 (0)
›
Associations
(2)
News
Trials
VERI cancer hierarchy
Reset Filters
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
MK-1084
Sensitive: C2 – Inclusion Criteria
MK-1084
Sensitive
:
C2
MK-1084
Sensitive: C2 – Inclusion Criteria
MK-1084
Sensitive
:
C2
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
pembrolizumab + MK-1084
Sensitive: C3 – Early Trials
pembrolizumab + MK-1084
Sensitive
:
C3
pembrolizumab + MK-1084
Sensitive: C3 – Early Trials
pembrolizumab + MK-1084
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login